Roche Aktie
| 254,50CHF | -1,70CHF | -0,66% |
WKN: 855167 / ISIN: CH0012032048
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 100,00 |
| Roche Holding AG | 1,43 |
| Vanguard Total International Stock Index Fund | 1,37 |
| Vanguard Developed Markets Index Fund | 0,85 |
| Vanguard Institutional Total Intl. Stock Market Index Tr. II | 0,68 |
| CSIF (CH) Umbrella - Eq. Switzerland Total Market Index Blue | 0,59 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 97 735 | 101 465 | 100 920 | 103 613 | 103 605 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,63 | 0,57 | 0,62 | 0,61 | 0,57 |
Bilanz (in Mio. CHF) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 31 254 | 32 942 | 35 627 | 33 816 | 33 446 |
| Summe Anlagevermögen | 51 837 | 53 196 | 56 690 | 54 335 | 57 022 |
| Summe Aktiva | 83 091 | 86 138 | 92 317 | 88 151 | 90 468 |
Bilanz (in Mio. CHF) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 15 582 | 15 411 | 32 552 | 26 544 | 30 782 |
| Summe Fremdkapital | 47 224 | 46 365 | 63 972 | 56 136 | 57 205 |
| Summe Eigenkapital | 35 867 | 39 773 | 28 345 | 32 015 | 33 263 |
| Summe Passiva | 83 091 | 86 138 | 92 317 | 88 151 | 90 468 |
Adresse
| Grenzacherstrasse 124, 4058 Basel | |
| Telefon | +41 (61) 688-11-11 |
| Internet | http://www.roche.com |
Management
|
Akiko Iwasaki
Director |
|
Alan Hippe
Chief Financial & Information Officer |
|
André S. Hoffmann
Vice Chairman |
|
Anita Hauser
Independent Non-Executive Director |
|
Boris Zaïtra
Head-Corporate Business Development |
|
Bruno Eschli
Head-Investor Relations |
|
Claudia Boeckstiegel
General Counsel |
|
Claudia Süssmuth Dyckerhoff
Independent Non-Executive Director |
|
Cristina A. Wilbur
Chief People Officer |
|
Hans Clevers
Head-Pharma Research & Early Development |
|
Jemilah Mahmood
Director |
|
Joerg Duschmale
Independent Non-Executive Director |
|
Levi A. Garraway
Chief Medical Officer & Head-Product Development |
|
Pascale Schmidt
Chief Compliance Officer |
|
Patrick Frost
Independent Non-Executive Director |
|
Per-Olof Attinger
Secretary |
|
Richard P. Lifton
Independent Non-Executive Director |
|
Severin Schwan
Chairman |
|
Silke Hörnstein
Head-Corporate Strategy & Sustainability |
|
Thomas Schinecker
Chief Executive Officer |
|
Ulf Mark Schneider
Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
